These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 36000302)

  • 1. Ocular toxicity following carboplatin chemotherapy for neuroendocrine tumour of the bladder.
    Ng J; Sadiq M; Mansoor Q
    J Oncol Pharm Pract; 2023 Apr; 29(3):768-771. PubMed ID: 36000302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bilateral Visual Impairment following Combination Chemotherapy with Carboplatin in Patients with Small Cell Lung Cancer: A Case Report.
    Kim J; Lee J; Lee S; Kim K
    Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929609
    [No Abstract]   [Full Text] [Related]  

  • 3. Optic neuritis induced by 5-fluorouracil chemotherapy: Case report and review of the literature.
    Raina AJ; Gilbar PJ; Grewal GD; Holcombe DJ
    J Oncol Pharm Pract; 2020 Mar; 26(2):511-516. PubMed ID: 31735134
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blinding Optic Neuropathy Associated With Carboplatin Therapy: A Case Report and Literature Review.
    Shihadeh S; Patrick MM; Postma G; Trokthi B; Maitland C
    Cureus; 2024 Jan; 16(1):e52975. PubMed ID: 38406141
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe ocular and orbital toxicity after intracarotid injection of carboplatin for recurrent glioblastomas.
    Watanabe W; Kuwabara R; Nakahara T; Hamasaki O; Sakamoto I; Okada K; Minamoto A; Mishima HK
    Graefes Arch Clin Exp Ophthalmol; 2002 Dec; 240(12):1033-5. PubMed ID: 12483326
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer.
    Gupta A; Long JB; Chen J; Gross CP; Feldman DR; Steingart RM
    J Urol; 2016 Jan; 195(1):33-40. PubMed ID: 26341576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy with cisplatin, carboplatin, and etoposide in advanced malignancy: a phase I trial.
    Rajkumar SV; Frytak S; Rubin J; Camoriano JK; Fitch TR
    Am J Clin Oncol; 1997 Oct; 20(5):500-4. PubMed ID: 9345336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [How to treat well differentiated endocrine carcinoma with a high proliferative index? A case of gastric endocrine carcinoma].
    Stefanescu C; Mathieu N; Bouarioua N; Abbey-Toby A; Karila Cohen P; Chosidow D; Soulé JC; Aparicio T
    Gastroenterol Clin Biol; 2006 May; 30(5):798-800. PubMed ID: 16801910
    [No Abstract]   [Full Text] [Related]  

  • 9. Risk-adapted chemotherapy of germ cell tumors with carboplatin, etoposide and bleomycin for low-risk and cisplatin, etoposide and ifosfamide for high-risk patients. A single-center study.
    Tscherry G; Jacky E; Jost LM; Stahel RA
    Oncology; 2000 Aug; 59(2):110-7. PubMed ID: 10971168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer.
    Lund B; Hansen OP; Hansen HH; Hansen M
    Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma.
    Bellmunt J; Ribas A; Eres N; Albanell J; Almanza C; Bermejo B; Solé LA; Baselga J
    Cancer; 1997 Nov; 80(10):1966-72. PubMed ID: 9366300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective study of definitive chemoradiotherapy in patients with resectable small cell neuroendocrine carcinoma of the esophagus.
    Katada C; Komori S; Yoshida T; Kawakami S; Watanabe A; Ishido K; Azuma M; Wada T; Hosoda K; Yamashita K; Hiki N; Tanabe S; Ishiyama H; Koizumi W
    Esophagus; 2020 Apr; 17(2):135-140. PubMed ID: 31321580
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe ocular and orbital toxicity after intracarotid etoposide phosphate and carboplatin therapy.
    Lauer AK; Wobig JL; Shults WT; Neuwelt EA; Wilson MW
    Am J Ophthalmol; 1999 Feb; 127(2):230-3. PubMed ID: 10030580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study.
    Bajorin DF; Sarosdy MF; Pfister DG; Mazumdar M; Motzer RJ; Scher HI; Geller NL; Fair WR; Herr H; Sogani P
    J Clin Oncol; 1993 Apr; 11(4):598-606. PubMed ID: 8386751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unilateral visual impairment in a patient undergoing chemotherapy: a case report and clinical findings.
    Yuan X; Feng Y; Li D; Li M
    BMC Ophthalmol; 2019 Nov; 19(1):236. PubMed ID: 31752765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I study of high-dose ifosfamide, carboplatin and etoposide with autologous hematopoietic stem cell support.
    Elias AD; Ayash LJ; Wheeler C; Schwartz G; Tepler I; Gonin R; McCauley M; Mazanet R; Schnipper L; Frei E
    Bone Marrow Transplant; 1995 Mar; 15(3):373-9. PubMed ID: 7599561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study.
    Skarlos DV; Samantas E; Kosmidis P; Fountzilas G; Angelidou M; Palamidas P; Mylonakis N; Provata A; Papadakis E; Klouvas G
    Ann Oncol; 1994 Sep; 5(7):601-7. PubMed ID: 7993835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206.
    Kelley MJ; Bogart JA; Hodgson LD; Ansari RH; Atkins JN; Pang H; Green MR; Vokes EE
    J Thorac Oncol; 2013 Jan; 8(1):102-8. PubMed ID: 23196276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.